Yun Fan

Tongji University — China

Medicine · Health Sciences

27h-index2.7kcitations213works4.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(124), Lung Cancer Research Studies(96), Cancer Immunotherapy and Biomarkers(55), Colorectal Cancer Treatments and Studies(28), Cancer Genomics and Diagnostics(17)

Publications213 total

Efficacy and Safety of Atezolizumab Plus Bevacizumab in Patients With Advanced <scp>NSCLC</scp> Who Received Pretreatment With <scp>EGFR</scp> ‐ <scp>TKIs</scp> ( <scp>ML41256</scp> ): A Multicenter, Prospective, Single‐Arm, Phase 2 Trial
Cancer Medicine·2025Open Access
Tislelizumab plus sitravatinib or anlotinib as maintenance therapy in extensive‐stage small‐cell lung cancer: Results of two prospective phase <scp>II</scp> studies
International Journal of Cancer·2025Open Access
P3.12.65 First-Line Osimertinib ± Platinum-Pemetrexed in EGFR-Mutated Advanced NSCLC: FLAURA2 Clinical Outcomes by EGFRm Subtype
Journal of Thoracic Oncology·2025Open Access
P2.06.55 Association Between Pathologic Necrosis and Postoperative Recurrence in Stage IA Non-Small Cell Lung Cancer
Journal of Thoracic Oncology·2025
EP.13.23 Tislelizumab Plus Sitravatinib or Anlotinib as Maintenance Therapy in Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)
Journal of Thoracic Oncology·2025
P3.12.48 Efficacy and Safety of Savolitinib in Advanced or Metastatic METex14 NSCLC Patients With or Without Prior Immunotherapy
Journal of Thoracic Oncology·2025
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non–Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)
Journal of Clinical Oncology·2025· 5 cited
WITHDRAWN: 1968P MedSR (median short fragment ratio): A novel fragmentomics biomarker for predicting prognosis in advanced EGFR-mutant lung cancer
Annals of Oncology·2025
Comparative investigation of neoadjuvant chemoimmunotherapy versus perioperative (chemo)immunotherapy in resectable non-small cell lung cancer: a real-world retrospective cohort study
Translational Lung Cancer Research·2025Open Access
Enhanced insecticidal efficacy and grain quality through optimized ozone adsorption in stored grain
LWT·2025· 1 citedOpen Access
[Comparison of the efficacy, safety, and cost-effectiveness of trastuzumab biosimilar HLX02 and the originator combined with pertuzumab and chemotherapy in the neoadjuvant treatment of patients with HER-2-positive breast cancer].
PubMed·2025
1475-P: Proteome-Wide Interaction Study of Circulating Proteins with APOE ε4 Genotypes for Diabetes Risk—A Prospective Cohort Study
Diabetes·2025
Survival and prognostic factors of HER2-mutant advanced non-small cell lung cancer with brain metastases
Lung Cancer·2025· 1 cited
Chinese Expert Consensus on Leptomeningeal Metastases of Lung Cancer
Thoracic Cancer·2025· 2 citedOpen Access
Efficacy and safety of pralsetinib in <i>RET</i> fusion-positive solid tumors: Final data from the ARROW trial.
Journal of Clinical Oncology·2025
Sacituzumab tirumotecan (sac-TMT) in combination with tagitanlimab (anti-PD-L1) in first-line (1L) advanced non-small-cell lung cancer (NSCLC): Non-squamous cohort from the phase II OptiTROP-Lung01 study.
Journal of Clinical Oncology·2025· 1 cited
A four gene risk score model for prognosis and immune microenvironment insights in small cell lung cancer based on CAF functional-related genes
Discover Oncology·2025Open Access
Genetic biomarker study of sunvozertinib for clinical prognosis and prediction in NSCLC with EGFR exon 20 insertion mutation
Cell Reports Medicine·2025· 4 citedOpen Access
Research progress on new physical therapies for cancer (Review)
Oncology Letters·2025Open Access
Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials
Nature Medicine·2025· 27 cited
page 1 of 11Next →

Frequent Co-authors

Zhiyu Huang(9), Jianying Zhou(8), Yanjun Xu(8), Kaiyan Chen(7), Jian Fang(6), Jianxing He(6), Yanqiu Zhao(6), Jun‐Fang Lin(6), Lin Wu(6), Ying Cheng(6), Zhiwei Ye(5), Li‐Qiong Guo(5), Renhua Guo(5), Yi‐Long Wu(5), Xiaoqing Yu(5), Xingya Li(4), Yongqian Shu(4), Yanping Hu(4), Jun Zhao(4), Yong Song(4)